Many catalysts - and you don't need them all:
- Direct sales of Alusion, given changes to Merck agreement (rather than exclusively through Merck). Apple patents are not guaranteed, but have potential
- Increased sales of Zinclear as beaches and tourism open up post-corona
- Dr Zinx and Zinc Gluconate sales (not sure how much margin these products have, or if they're just a path to use more Zinc Oxide)
- Additional cosmetics with SPF (alone this probably isn't that meaningful)
The top two in particular are very promising.
And whilst sunscreen sales have tanked during lockdowns, this short-term impact might be a longer-term gift. Not too many competitors would be as ready as ANO for the reversion to the mean.
Finally, we also know competitors products are more expensive. $35-50USD was the quoted price, with Zinclear much cheaper. Now they have a range of cheaper powders and dispersions - it's just a matter of winning more market share over time (and winning new products coming to market).
Best of all, expansion is cheap - much cheaper than Everzinc spent on their expansion.
@throwerw is correct. ANO is dominating an established market - just that the market has temporarily slowed.
